Genetic Engineering & Biotechnology News, Sept. 26, 2007 VaxInnate Corporation has commenced its first Phase 1 clinical trial, testing its M2e universal influenza vaccine. Principal investigator Lawrence R. Stanberry, chairman of UTMB's Department of Pediatrics and director of the Sealy Center for Vaccine Development, said, "We believe VaxInnate's approach to vaccine development has the potential to provide developing countries and regions with influenza vaccines that are less expensive and more effective than currently available alternatives." This study is supported by a $9.5 million grant from the Bill & Melinda Gates Foundation to UTMB to better control influenza epidemics in the developing world.